Max P Kristiansen

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang et al. · The Lancet Infectious Diseases · 2019 · 190 citations

Vaccination, Mucosal Vaccination, Caf01 Liposomes +4

Bordetella pertussis and Chronic Cough in Adults

Max P Kristiansen, Torben Seefeldt, J. Degn et al. · Clinical Infectious Diseases · 1999 · 143 citations · Full text

Vaccination, B. Pertussis Infection, B. Pertussis Reservoirs +11

Improved ELISA for determination of anti‐diphtheria and/or anti‐tetanus antitoxin antibodies in sera

Max P Kristiansen, Henrik Aggerbeck, Iver Heron · Apmis · 1997 · 89 citations

A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

Synne Jenum, Kristian Tonby, Corina S. Rueegg et al. · Nature Communications · 2021 · 64 citations · Full text

Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus.

Michael S. Deming, J. B. Roungou, Max P Kristiansen et al. · PubMed · 2002 · 39 citations · Full text